BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17919914)

  • 1. Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.
    Castro A; Encinas A; Gil C; Bräse S; Porcal W; Pérez C; Moreno FJ; Martínez A
    Bioorg Med Chem; 2008 Jan; 16(1):495-510. PubMed ID: 17919914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
    Martinez A; Alonso M; Castro A; Pérez C; Moreno FJ
    J Med Chem; 2002 Mar; 45(6):1292-9. PubMed ID: 11881998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
    Martinez A; Alonso M; Castro A; Dorronsoro I; Gelpí JL; Luque FJ; Pérez C; Moreno FJ
    J Med Chem; 2005 Nov; 48(23):7103-12. PubMed ID: 16279768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
    Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.
    Perez DI; Conde S; Pérez C; Gil C; Simon D; Wandosell F; Moreno FJ; Gelpí JL; Luque FJ; Martínez A
    Bioorg Med Chem; 2009 Oct; 17(19):6914-25. PubMed ID: 19747834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of glioblastoma growth by the thiadiazolidinone compound TDZD-8.
    Aguilar-Morante D; Morales-Garcia JA; Sanz-SanCristobal M; Garcia-Cabezas MA; Santos A; Perez-Castillo A
    PLoS One; 2010 Nov; 5(11):e13879. PubMed ID: 21079728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors.
    Rosa AO; Egea J; Martínez A; García AG; López MG
    Exp Neurol; 2008 Jul; 212(1):93-9. PubMed ID: 18471812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode.
    Zou H; Zhou L; Li Y; Cui Y; Zhong H; Pan Z; Yang Z; Quan J
    J Med Chem; 2010 Feb; 53(3):994-1003. PubMed ID: 20030405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.
    Conde S; Pérez DI; Martínez A; Perez C; Moreno FJ
    J Med Chem; 2003 Oct; 46(22):4631-3. PubMed ID: 14561081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse.
    Cuzzocrea S; Mazzon E; Di Paola R; Muià C; Crisafulli C; Dugo L; Collin M; Britti D; Caputi AP; Thiemermann C
    Clin Immunol; 2006 Jul; 120(1):57-67. PubMed ID: 16631408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamides as selective GSK-3 inhibitors.
    Koryakova AG; Ivanenkov YA; Ryzhova EA; Bulanova EA; Karapetian RN; Mikitas OV; Katrukha EA; Kazey VI; Okun I; Kravchenko DV; Lavrovsky YV; Korzinov OM; Ivachtchenko AV
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3661-6. PubMed ID: 18502121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3β.
    Cociorva OM; Li B; Nomanbhoy T; Li Q; Nakamura A; Nakamura K; Nomura M; Okada K; Seto S; Yumoto K; Liyanage M; Zhang MC; Aban A; Leen B; Szardenings AK; Rosenblum JS; Kozarich JW; Kohno Y; Shreder KR
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5948-51. PubMed ID: 21873061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marine Fungi as Producers of Benzocoumarins, a New Class of Inhibitors of Glycogen-Synthase-Kinase 3β.
    Wiese J; Imhoff JF; Gulder TA; Labes A; Schmaljohann R
    Mar Drugs; 2016 Oct; 14(11):. PubMed ID: 27801816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
    Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
    Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 3-benzisoxazolyl-4-indolylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3β.
    Ye Q; Li M; Zhou Y; Pang T; Xu L; Cao J; Han L; Li Y; Wang W; Gao J; Li J
    Molecules; 2013 May; 18(5):5498-516. PubMed ID: 23669633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta.
    Whittle BJ; Varga C; Pósa A; Molnár A; Collin M; Thiemermann C
    Br J Pharmacol; 2006 Mar; 147(5):575-82. PubMed ID: 16314851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.